Microbiome Competitive Landscape, Pipeline, Clinical Trials, and Key Companies | Companies – Ferring Pharmaceuticals, Miyarisan Pharmaceutical, Seres Therapeutics, 4D Pharma, Caelus Health, MRM Health,

 Breaking News
  • No posts were found

Microbiome Competitive Landscape, Pipeline, Clinical Trials, and Key Companies | Companies – Ferring Pharmaceuticals, Miyarisan Pharmaceutical, Seres Therapeutics, 4D Pharma, Caelus Health, MRM Health,

June 07
13:32 2023
Microbiome Competitive Landscape, Pipeline, Clinical Trials, and Key Companies | Companies - Ferring Pharmaceuticals, Miyarisan Pharmaceutical, Seres Therapeutics, 4D Pharma, Caelus Health, MRM Health,
DelveInsight Business Research LLP
(United States, Nevada, Las Vegas), DelveInsight’s, Microbiome Competitive Landscape, 2023,” report provides comprehensive insights about 130+ companies and 180+ drugs in Microbiome Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Microbiome Competitive Landscape Report

  • Over 130+ companies and 180+ pipeline drugs in Microbiome Competitive landscape. 

  • Leading Microbiome companies developing novel drug candidates to improve the Microbiome treatment landscape include Ferring Pharmaceuticals, Miyarisan Pharmaceutical, Seres Therapeutics, 4D Pharma, Caelus Health, MRM Health, Scioto Biosciences, Adiso Therapeutics, and many others.

  • Servatus Biopharmaceuticals

  • Promising PD-1 and PD-L1 Inhibitors pipeline therapies in various stages of development include RBX 2660, SER-109, Blautix, SER-301, and many others.

Microbiome Overview

Microbiome refers to the collection of microbes and their interaction with the human body. The microbiome plays an important role in human physiology and disease. The microbes and their interaction with the human body show the various aspects of human biology. The human body possesses a number of different species particularly bacteria and fungi which help in digesting food, preventing infections, and performing numerous life-supporting tasks. Microbes can also be harmful to their human hosts. Role of Microbiota in Health and Disease in Metabolic Disorders.

 Microbiome Pipeline Therapies and Key Companies

  •  Ferring pharmaceuticals: RBX 2660

  •  Seres Therapeutics: SER-109

  •  4D Pharma: Blautix

  And many others 

 

Scope of the PD-1 and PD-L1 Inhibitors  Pipeline Report 

  • Coverage: Global 

  • Key Microbiome Companies: Intor Pharma, Eli Lilly and Company, Addpharma, TechnoDerma Medicines, Energenesis Biomedical, Pfizer, Biosplice Therapeutics, Inc., Concert Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, Legacy Healthcare SA, Eurofarma Laboratorios S.A., 3SBio, Arena Pharmaceuticals, AnaptysBio, Inc., Reistone Biopharma Company Limited, Biosplice Therapeutics, Inc., LEOPharma, Intrepid Therapeutics and others.

  • Key Microbime Pipeline Therapies:  KX-826, Baricitinib, Etrasimod, Dutasteride, TDM-105795,Baricitinib, ENERGI-F701, Regaine, CKD-498 ,  CTP-543, PF-06651600 and others.

Find out more about the PD-1 and PD-L1 Inhibitors   treatment options in development @ Microbiome Clinical Trials

Table of Contents

Introduction

Executive Summary

Microbiome: Overview

  • Introduction

  • Mechanism of Action

  • Application

  • Limitation

  • Approved Therapies

Microbiome: In-depth Commercial Assessment

  • Microbiome Collaboration Analysis by Companies

Competitive Landscape

  • Comparative Assessment of Companies (by therapy, development stage, and technology)

Therapeutic Assessment

  • Assessment by Product Type

  • Assessment by Stage and Product Type

  • Assessment by Route of Administration

  • Assessment by Stage and Route of Administration

  • Assessment by Molecule Type

  • Assessment by Stage and Molecule Type

Microbiome: Company and Product Profiles (Marketed Therapies)

JW Therapeutics

  • Company Overview

Relmacabtagene autoleucel

  • Product Description

  • Research and Development Activities

  • Product Developmental Activities

Microbiome: Company and Product Profiles (Pipeline Therapies)

Late Stage Products (Registered)

  • Comparative Analysis

CARsgen

  • Company Overview

Zevorcabtagene autoleucel

  • Product Description

  • Research and Development Activities

  • Product Developmental Activities

Mid-Stage Products (Phase II)

  • Comparative Analysis

Cartesian Therapeutics

  • Company Overview

Descartes 011

  • Product Description

  • Research and Development Activities

  • Product Developmental Activities

Early Stage Products (Phase I)

  • Comparative Analysis

Autolus Therapeutics

  • Company Overview

AUTO-8

  • Product Description

  • Research and Development Activities

  • Product Developmental Activities

Preclinical and Discovery Stage Products

  • Comparative Analysis

Sana Biotechnology

  • Company Overview

SG299

  • Product Description

  • Research and Development Activities

  • Product Developmental Activities

Inactive Products

  • Comparative Analysis

Microbiome – Unmet needs

Microbiome – Market drivers and barriers

Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Categories